-
Mashup Score: 0
New analyses from the PEACE-1 and STAMPEDE multicenter trials demonstrated that the addition of abiraterone acetate plus prednisolone to standard-of-care therapy improves survival in castration-sensitive prostate cancer.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
For second-line treatment of metastatic HER2-positive breast cancer, the new-generation antibody drug conjugate (ADC) trastuzumab deruxtecan-nxki (T-DXd) is far more effective than the older-generation ADC trastuzumab emtansine (T-DM1), according to data from the first head-to-head comparison of ADCs for any malignancy, not just breast cancer.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Data from the first head-to-head comparison of antibody drug conjugate’s found the new-generation more effective for metastatic breast cancer. https://t.co/VgU0wOCvOr @JavierCortesMD @sloan_kettering #breastcancer #ESMO2021
-
-
Mashup Score: 8Oliver Dorigo, MD @Stanford @StanfordCancer @imv_inc #A - 4 year(s) ago
Oliver Dorigo, MD, Principal Investigator of the DeCidE1 study and Director of the Gynecologic Oncology Service at Stanford University speaks about the IMV
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer and the updated data from ESMO 2021 Oliver Dorigo, MD @Stanford @StanfordCancer @imv_inc #ASCOPubs #ESMO2021 #OvarianCancer #Cancer #Research https://t.co/YW16hP7X1S...?channelName=cancernewsupdate https://t.co/Jc8GjSjHSF
-
-
Mashup Score: 4Podcast - Oliver Dorigo, MD @Stanford @StanfordCancer @ - 4 year(s) ago
Oliver Dorigo, MD, Principal Investigator of the DeCidE1 study and Director of the Gynecologic Oncology Service at Stanford University speaks about the IMV
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Podcast - DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer and the updated data from ESMO 2021 Oliver Dorigo, MD @Stanford @StanfordCancer @imv_inc #ASCOPubs #ESMO2021 #OvarianCancer #Cancer Link to Audio: https://t.co/fpKtp0LuYD...?channelName=cancernewsupdate https://t.co/3wwMaO061K
-
-
Mashup Score: 2
The overall survival benefit with durvalumab plus etoposide and cisplatin/carboplatin versus EP alone for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) as demonstrated in the phase 3 CASPIAN trial was sustained beyond 3 y…
Source: www.mdedge.comCategories: General Medicine News, Latest HeadlinesTweet-
OS benefit with durvalumab plus etoposide and cisplatin/carboplatin versus EP alone for the first-line treatment of ES-SCLC was demonstrated by a new Phase 3 trial. https://t.co/x1V6tUMq9p #ESMO2021 https://t.co/uzAfYINOF7
-
-
Mashup Score: 0Use of Biomarkers to Optimize Treatment of NSCLC - 4 year(s) ago
Biomarkers have advanced the field of NSCLC by informing the choice of therapy. Physicians are urged to incorporate genetic profiling at diagnosis and progression to improve outcomes.
Source: www.mdedge.comCategories: General Medicine News, Latest HeadlinesTweet-
Benjamin Cooper, MD, Director of Proton Therapy at NYU Langone Health, discusses how docs who treat patients with NSCLC can use genetic profiling results to select effective therapy. https://t.co/TfS0Ayx1WG #ESMO2021 https://t.co/OtxxCHQGBi
-
-
Mashup Score: 0cLOD May Provide More Accurate Evaluation of Cell-Free DNA in Multi-Cancer Early Detection - 4 year(s) ago
Clinical limit of detection may be a reasonable metric for evaluating cell-free DNA for multi-cancer early detection.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Clinical limit of detection may be a reasonable metric for evaluating cell-free DNA for multi-cancer early detection. @myESMO #ESMO2021 #oncology https://t.co/1uzIxdIMrV
-
-
Mashup Score: 0
Tisotumab vedotin elicited significant responses without prohibitive toxicity in combination with carboplatin as frontline therapy, as well as in combination with pembrolizumab as second- or third-line therapy in patients with recurrent or metastatic cervical cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Tisotumab vedotin elicited significant responses w/o prohibitive toxicity in combo with carboplatin as frontline therapy, as well as in combo w/ pembro as 2nd/3rd-line therapy in pts w/ recurrent or metastatic cervical cancer. @myESMO #gyncsm #ESMO2021 https://t.co/USHisJqzfh
-
-
Mashup Score: 0Survival Benefit Found With Abiraterone/Prednisolone-Based Combos in High-Risk Nonmetastatic Prostate Cancer - 4 year(s) ago
When added to androgen-deprivation therapy, abiraterone acetate and prednisolone with or without enzalutamide for 2 years improved survival outcomes in men with high-risk nonmetastatic prostate cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
When added to androgen-deprivation therapy, abiraterone acetate and prednisolone with or without enzalutamide for 2 years improved survival outcomes in men with high-risk nonmetastatic prostate cancer. #pcsm #ESMO2021 @myESMO https://t.co/qzwBfDtCP2
-
-
Mashup Score: 3Atezolizumab Plus Cabozantinib Shows Meaningful Clinical Activity in mCRPC, Including High-Risk Subsets - 4 year(s) ago
The phase 1b COSMIC-021 trial showed clinically meaningful activity with cabozantinib plus atezolizumab in patients with locally advanced or metastatic castration-resistant prostate cancer who have been previously treated, including patients with high-risk features.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The COSMIC-021 trial showed activity w/ cabozantinib plus atezolizumab in pts w/ locally advanced or mCRPC who have been previously treated, including patients with high-risk features. @neerajaiims @huntsmancancer @myESMO #ESMO2021 #lcsm https://t.co/dbYxkAEUY3
-
Analysis of prostate cancer trials data demonstrated that the addition of abiraterone acetate plus prednisolone to standard-of-care therapy improves survival. https://t.co/d9ZRRUTl74 @MDAndersonNews #prostatecancer #ESMO2021